Journal: Biomolecules and Biomedicine
Article Title: Glioblastoma induces CAF-like astrocyte activation via the AKT/mTOR–SERPINH1/COL5A1 axis
doi: 10.17305/bb.2025.11898
Figure Lengend Snippet: The expression of SERPINH1/ COL5A1 and AKT/m-TOR pathway in a GBM and astrocytes co-culture model. (A) KEGG pathway enrichment. (B) Western blot shows the expression of the AKT/m-TOR pathway in co-cultured SVGP12 cells (p-mTOR: SVGP12, 1 ± 0, n ═ 3; SVGP12-U87, 4.776 ± 0.467, n ═ 3; SVGP12-T98G, 3.234 ± 0.316, n ═ 3; SVGP12-LN229, 1.497 ± 0.349, n ═ 3; SVGP12-U343, 5.107 ± 0.456, n ═ 3. mTOR: SVGP12, 1 ± 0, n ═ 3; SVGP12-U87, 1.367 ± 0.054, n ═ 3; SVGP12-T98G, 1.349 ± 0.043, n ═ 3; SVGP12-LN229, 1.350 ± 0.330, n ═ 3; SVGP12-U343, 1.261 ± 0.438, n ═ 3. p-AKT: SVGP12, 1 ± 0, n ═ 3; SVGP12-U87, 1.847 ± 0.168, n ═ 3; SVGP12-T98G, 1.880 ± 0.152, n ═ 3; SVGP12-LN229, 1.877 ± 0.053, n ═ 3; SVGP12-U343, 2.127 ± 0.213, n ═ 3. AKT: SVGP12, 1 ± 0, n ═ 3; SVGP12-U87, 1.089 ± 0.287, n ═ 3; SVGP12-T98G, 1.075 ± 0.044, n ═ 3; SVGP12-LN229, 1.183 ± 0.269, n ═ 3; SVGP12-U343, 1.237 ± 0.077, n ═ 3). (C) Western blot shows AKT/m-TOR pathway expression in peritumor and normal tissues of GBM mice (p-mTOR: Normal, 1 ± 0, n ═ 3; Peritumor, 2.578 ± 0.981, n ═ 3. mTOR: Normal, 1 ± 0, n ═ 3; Peritumor,0.944 ± 0.413, n ═ 3. p-AKT: Normal, 1 ± 0, n ═ 3; Peritumor, 1.554 ± 0.349, n ═ 3. AKT: Normal, 1 ± 0, n ═ 3; Peritumor, 1.011 ± 0.218, n ═ 3). (D) Western blot shows SERPINH1 and COL5A1 expression in SVGP12 cells treated with the AKT agonist sc79 (SERPINH1: SVGP12, 1 ± 0, n ═ 3; SVGP12+SC79, 5.263 ± 0.584, n ═ 3. COL5A1: SVGP12, 1 ± 0, n ═ 3; SVGP12+SC79, 1.160 ± 0.033, n ═ 3). (E) Migration of SVGP12 cells treated with the AKT agonist sc79 (right) and of untreated SVGP12 cells (left). (F and G) Western blot shows the expression of the AKT-mTOR pathway (F) (p-mTOR: SVGP12, 1 ± 0, n ═ 3; SVGP12+Perifosine, 0.782 ± 0.007, n ═ 3; SVGP12-U87+Perifosine, 0.812 ± 0.018, n ═ 3; SVGP12-T98G+Perifosine, 0.588 ± 0.026, n ═ 3; SVGP12-LN229+Perifosine, 0.451 ± 0.035, n ═ 3; SVGP12-U343+Perifosine, 0.574 ± 0.023, n ═ 3. p-AKT: SVGP12, 1 ± 0, n ═ 3; SVGP12+Perifosine, 0.555 ± 0.036, n ═ 3; SVGP12-U87+Perifosine, 0.690 ± 0.006, n ═ 3; SVGP12-T98G+Perifosine, 0.714 ± 0.030, n ═ 3; SVGP12-LN229+Perifosine, 0.665 ± 0.023, n ═ 3; SVGP12-U343+Perifosine, 0.677 ± 0.021, n ═ 3) and that of SERPINH1 and COL5A1 (G) in co-cultured SVGP12 cells, and in co-cultured SVGP12 cells treated with the AKT inhibitor perifosine (SERPINH1: SVGP12, 1 ± 0, n ═ 3; SVGP12+Perifosine, 0.876 ± 0.048, n ═ 3; SVGP12-U87+Perifosine, 0.959 ± 0.023, n ═ 3; SVGP12-T98G+Perifosine, 0.817 ± 0.050, n ═ 3; SVGP12-LN229+Perifosine, 0.748 ± 0.070, n ═ 3; SVGP12-U343+Perifosine, 0.807 ± 0.046, n ═ 3.COL5A1:SVGP12, 1 ± 0, n ═ 3; SVGP12+Perifosine, 0.868 ± 0.072, n ═ 3; SVGP12-U87+Perifosine, 0.923 ± 0.034, n ═ 3; SVGP12-T98G+Perifosine, 0.859 ± 0.074, n ═ 3; SVGP12-LN229+Perifosine, 0.920 ± 0.011, n ═ 3; SVGP12-U343+Perifosine, 0.830 ± 0.028, n ═ 3). (H) Statistical graph of changes in SERPINH1 and COL5A1 protein expression with the addition of perifosine. The experiment was repeated three times, and the results are representative of three independent experiments. The statistical results are shown in Figure S7 . In the statistical figures, P values are indicated with asterisks, where * represents P < 0.05, ** represents P < 0.01, ***represents P < 0.001, and **** represents P < 0.0001. GBM: Glioblastoma multiforme; KEGG: Kyoto Encyclopedia of Genes and Genomes.
Article Snippet: The membrane was blocked with 5% bovine serum albumin (BSA) (ST023, Beyotime, China) in TBST for 2 h and then incubated overnight at 4 ∘ C with the following primary antibodies: SERPINH1 (sc-5293, Santa Cruz, 1:1000), COL5A1 (sc-133162, Santa Cruz, 1:1000), GAPDH (GB15002, Servicebio, 1:2000), AKT (#4685, CST, 1:1000), P-AKT (#4060, CST, 1:1000), mTOR (ET1608-5, HUABIO, 1:1000), P-mTOR ( HA600094 , HUABIO, 1:1000), FAP (AF5344, Affinity, 1:800), and S100A4 (CY5799, Abways, 1:1000).The membrane was then incubated for 3 h at 4 ∘ C with the following secondary antibodies: HRP-conjugated Goat Anti-Mouse IgG(H+L) (A0216, Beyotime, 1:1000) and HRP-conjugated Goat Anti-Rabbit IgG(H+L) (A0208, Beyotime, 1:1000).
Techniques: Expressing, Co-Culture Assay, Western Blot, Cell Culture, Migration